Call (954) 551-3508
1911 Harrison Street, Hollywood, FL 33020
By Dr. Sergey Terushkin, MD, FACS
As a bariatric surgeon and weight-loss specialist, I’ve watched the evolution of obesity treatment for over a decade. While surgery remains the most powerful tool for long-term weight control, a majority of qualifying patients never proceed due to fear, cost, or recovery concerns. GLP-1 medications changed everything — and Retatrutide may represent the next major leap.
This investigational peptide combines three metabolic pathways, delivering fat-loss outcomes that surpass every medication currently available.
Retatrutide is an investigational triple-receptor agonist developed by Eli Lilly. It simultaneously activates:
This “three-lane” approach makes Retatrutide fundamentally different from other medications, potentially placing it closer to bariatric-surgery outcomes — but without surgery.
When injected weekly, the peptide communicates with metabolic receptors that influence:
Patients in clinical trials typically report suppressed appetite, earlier satiety, and steadily progressing fat loss week after week.
Learn About Retatrutide Dose Escalation Chart & Units Calculator for Weight Loss
In a pivotal study published in the New England Journal of Medicine, Retatrutide produced:
(in non-diabetic participants)
For comparison:
That is a level of weight loss previously achievable mostly with surgery.
Clinical dosing used in trials:
| Week | Dose | Frequency | Notes |
|---|---|---|---|
| 1–4 | 2.5 mg | Weekly | Starting dose |
| 5–8 | 5 mg | Weekly | Titration |
| 9–12 | 7.5 mg | Weekly | Smooth escalation |
| 13+ | 10 mg | Weekly | Full therapeutic range |
Final FDA-approved dosing may differ.
Affordable GLP-1 Weight Loss — Telehealth Care for Every Patient in Florida and Beyond
Call Today (954) 551-3508 Or Book Online
Most side effects were mild to moderate:
These are consistent with the GLP-1 class of medications.
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| GLP-1 | ✔ | ✔ |
| GIP | ✔ | ✔ |
| Glucagon | ✘ | ✔ (unique advantage) |
| Fat-Loss Power | Very high | Highest in trials |
While Retatrutide is still in development, many leading obesity specialists and bariatric physicians have shared cautious optimism:
“Retatrutide appears to deliver weight-loss results that rival bariatric procedures. The triple-receptor activation is something we’ve predicted would be the next evolution in obesity pharmacology.”
“Tirzepatide changed the field. Retatrutide may redefine it. Glucagon activation is the missing piece, allowing much faster fat mobilization while still controlling appetite.”
“We are seeing the highest percentage weight reductions ever recorded in medication-based therapy. If phase 3 results hold, Retatrutide may become the gold standard.”
Retatrutide is investigational and not FDA-approved, so it is not covered by insurance in Florida. Coverage may be considered only if the medication receives FDA approval in the future. Patients should discuss currently approved, potentially covered weight loss options with their physician.
“Retatrutide represents a major medical breakthrough. Until FDA approval, our priority remains offering patients safe, effective, accessible weight-loss solutions that work today.”
The medication does not walk the path for the patient. It opens the door. The patient, supported by the right medical team, must choose to step through it.
Our medical weight loss program proudly serves patients throughout South, Central, and North Florida with both in-office and secure telehealth consultations.
Hollywood, Hallandale Beach, Aventura, Pembroke Pines, Fort Lauderdale, Miami, Dania Beach, Davie, Weston, Miramar, Coral Springs, Boca Raton, Delray Beach, Boynton Beach, West Palm Beach, Palm Beach Gardens.
Orlando, Kissimmee, Winter Park, Clermont, Tampa, St. Petersburg, Clearwater, Lakeland, Brandon, Sarasota, Bradenton, Ocala, The Villages, Daytona Beach, Melbourne, Port St. Lucie.
Jacksonville, St. Augustine, Gainesville, Tallahassee, Pensacola, Panama City, Destin, Fort Walton Beach.
We offer physician-supervised weight loss programs including GLP-1–based treatments, tirzepatide, semaglutide, metabolic evaluations, and structured medical weight management plans. Insurance verification and self-pay options are available.
Patients anywhere in Florida can schedule a consultation to determine eligibility and receive a personalized treatment plan under medical supervision.
Retatrutide is currently in clinical trials and has not been evaluated or approved by the U.S. Food & Drug Administration (FDA) for general medical use. All details provided are for educational and informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. Patients should consult a licensed healthcare provider for personalized recommendations.
• Learn more about GLP-1/GIP/Glucagon triple-agonist therapies
Triple–Hormone-Receptor Agonist Retatrutide for Obesity
• See how Retatrutide compares to Semaglutide & Tirzepatide
Eli Lilly Overview of Retatrutide Mechanism & Research
• Background on Triple-Agonist Peptide Development
Scientific Review: Triple-Hormone Agonists for Obesity
• Safety profile and metabolic benefits overview
PubMed: Retatrutide Safety, Tolerability & Metabolic Outcomes
• Patient-friendly explanation of emerging weight-loss peptides
•FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Real people, REAL RESULTS! Check out a few of the many people that we have helped reach their ideal weight goals over the years.
A World-Class Group Of Board Certified Providers Dedicated to You! With weight-loss surgery, you deserve a team of renowned experts at your back, guiding your transformation journey with your whole health in mind. And that’s exactly the kind of support you’ll find here.
